Jonathan Faison
Contributor since: 2011
Latest Articles
Bellerophon Therapeutics: INOpulse Gets A Shot At Redemption
Affimed Therapeutics: Continued Upside Ahead
Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data
Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms
ViewRay: Buy The Secondary
Magenta Therapeutics: This June IPO Should Be On Your Radar
Constellation Pharmaceuticals: A Recent IPO Of Interest
Scholar Rock: Value Waiting To Be Unlocked In This May IPO's Pipeline
Zafgen: This Revaluation And Catalyst Story Is Still In Early Innings
Checkpoint Therapeutics: Potential For A Near-Term Run Up
BioDelivery Sciences: Buy The Dip
Soleno Therapeutics: Rare Disease Pick With Significant Potential And Low Valuation
Savara: Buy The Secondary
uniQure: Buy The Dip
Applied Genetic Technologies Corporation: Near-Term Run Up Expected
Invuity: Turnaround In Progress
Viking Therapeutics: Thesis Strengthens, Catalysts In Focus
Arbutus Biopharma: Run Up Continues, Catalyst In Focus
ArQule: Continued Upside As Additional Catalysts Loom
Krystal Biotech: Data Due Year-End
Biotech: Take It On The Run
Zafgen Update: After Financing, Continued Revaluation Ahead
Gemphire Therapeutics: Financing Likely, NASH/NAFLD Opportunity In Focus
InflaRx: Buy The Dip
Eiger BioPharmaceuticals: Buy The Dip
Sunesis Pharmaceuticals: A Run-Up Interrupted Set To Resume?
Infinity Pharmaceuticals: Cheap With A Key Data Readout Coming
Aptinyx: This Recent IPO Should Be On Your Radar
Intec Pharma: Is It Time To Go Bottom Fishing?
Institutional Top Ideas: Great Point Partners
Kadmon Holdings: Secondary Offering Points To Revaluation Opportunity
Clearside Biomedical: Upside Into Q4 Data And NDA Submission